Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced that it will participate in the 20th
Annual Australasian Society of Cataract and Refractive Surgeons (AUSCRS)
Conference. Dr. Wayne Crewe-Brown, one of the world's most accomplished
laser eye surgeons who also has the most experience performing the
Presbia Flexivue Microlens™ implant in a commercial setting, will be
conducting two educational presentations about the Presbia Flexivue
Microlens, a proprietary optical lens implant and an innovative solution
for treating the loss of near-vision. Dr. Crewe-Browne is also a member
of Presbia's Medical Advisory Board.
The annual AUSCRS conference, being held this year from July 20th
through the 23rd at the Sheraton Mirage, Port Douglas in
Queensland, Australia, presents up-to-date information on scientific
developments within the field of cataract and refractive surgery, and is
attended by AUSCRS members who are leading industry surgeons.
"Australia, New Zealand and South Korea are key markets for Presbia and
we are very pleased that we will have the opportunity at the conference
to expand the awareness of AUSCRS members of the Presbia Flexivue
Microlens as safe, effective and the best surgical treatment for
presbyopia," said Todd Cooper. "This meeting will accelerate our
expansion into these key countries and educate surgeons on the benefits
of our surgical solution to reduce the need for reading glasses."
Information provided and statements contained in this press release that
are not purely historical are forward-looking statements. Such
forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005176/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media